Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300839 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
A Phase 3 study of COVID-19 and SARS CoV 2 Infection, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 25,500
- Enrollment target
- 20
- Study locations
NCT07300839: Recruiting Phase 3 study of COVID-19 and SARS CoV 2 Infection, sponsored by BioNTech SE.
NCT07300839 is a Phase 3 study of COVID-19 and SARS CoV 2 Infection that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 25,500 participants, below the 38,379-participant average among 298 other COVID-19 trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07300839, a Phase 3 study of COVID-19 and SARS CoV 2 Infection, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 25,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL BNT162b2 Vaccine
Study Locations (20)
Alabama
- Pinnacle Research Group, LLC - Anniston
- North Alabama Research Center - Athens
- Simon Williamson Clinic / Synexus Clinical Research US, Inc. - Birmingham
- Accel Research Sites - Birmingham Clinical Research Unit - Birmingham
- Cullman Clinical Trials - Cullman
- AMR Clinical - Daphne
- Medical Affiliated Research Center - Huntsville
- AMR Clinical - Mobile
Arizona
- Chandler Clinical Trials - Chandler
- Synexus Clinical Research US, Inc. - Phoenix
- Scottsdale Clinical Trials - Scottsdale
- Epic Medical Research-Sun City - Sun City
- Noble Clinical Research - Tucson
- Synexus Clinical Research US, Inc./Orange Grove Family Practice - Tucson
California
- Anaheim Clinical Trials, LLC - Anaheim
- Velocity Clinical Research, Chula Vista - Chula Vista
- West Coast Research - Dublin
- Leading Edge Research LA - Encino
- Leading Edge Research - Encino
Arkansas
- Woodland International Research Group - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,500 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 3 |
What NCT07300839 shows while recruiting
NCT07300839 is an interventional study that assigns participants to a tested intervention. Its 25,500 participants enrollment target places it among the larger protocols in the corpus, below the 38,379-participant average among 298 other COVID-19 trials with a reported enrollment target (34% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07300839 names 20 study sites across 4 states, led by Alabama, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT07300839 about?
NCT07300839 is a clinical study titled "A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age". This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).
What is the current status of trial NCT07300839?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 25,500 participants. The study started on 2025-12-10. Estimated completion is 2026-07-31.
What conditions does trial NCT07300839 study?
This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection.
What interventions are being tested in trial NCT07300839?
The interventions under investigation include: Placebo (BIOLOGICAL), BNT162b2 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07300839?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07300839 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07300839's enrollment target sits among peer trials
25,500 14th of 298 higher than 285 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI